AI reads heart signals to simplify cancer drug monitoring
NCT ID NCT05623397
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether an artificial intelligence (AI) model can accurately measure heart rhythm changes (QTc) from ECGs in 70 breast cancer patients starting the drug ribociclib. The goal was to see if simpler ECG devices could work as well as standard 12-lead machines when analyzed by AI. The findings could make heart monitoring easier and more accessible during cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC - Hôpitaux Universitaires Pitié Salpêtrière, Paris, FRANCE
Paris, 75651, France
-
Groupe Ambroise Paré, Hartmann
Neuilly-sur-Seine, 92200, France
-
Hôpital Tenon
Paris, 75020, France
-
Institut Gustave Roussy
Villejuif, 94805, France